TASCⅡD型主髂动脉闭塞症腔内治疗进展

Progress in endovascular therapies of TASCⅡD aortoiliac oedusive disease

主髂动脉闭塞症是血管外科的常见病和多发病,动脉粥样硬化是其主要的发病原因。泛大西洋协作组织共识(TASCⅡ)D型主髂动脉闭塞症由于病变复杂,既往首选治疗方法是主动脉旁路移植术。随着治疗理念的变化、对吻支架研究的深人及重建主动脉分叉和一体式支架技术的引进,腔内治疗获得满意的短期和长期通畅率。目前腔内治疗已成为TASCIID型主髂动脉闭塞症首选治疗方法。本文对TASCⅡD型主髂动脉闭塞症的腔内治疗新进展进行综述。

Aortoiliac occlusive disease is a common and frequently-occurring disease of vascular surgery,and atherosclerosis is the main cause of its disease.Inter-Society Consensus for the Management of Peripheral Arterial Disease(TASCⅡ)D type of aortoiliac occlusive disease due to complex lesions,the preferred treatment method is aortobifemoral bypass.With the change of treatment concept,in-depth study of kiss stent,and the introduction of reconstruction of aortic bifurcation and integrated stent technology,endovascular therapies has achieved satisfactory short-term and long-term patency rates.At present,endovascular therapies has become the preferred treatment for TASCⅡD aortoiliac occlusive disease.This article reviews the recent advances in endovascular therapies of TASCⅡD aortoiliac occlusive disease.